دانلود کتاب اختلالات دستگاه تنفسی در کودکان کندیگ و ویلموت

Welcome to the new edition of Kendig, to which the distinguished name of Robert Wilmott has been added. This is his valedictory volume, having been involved in four previous editions, two as Editor in Chief. Bob has set us all high standards, which he himself has always achieved, not merely in Kendig, but in so many positions in academic and clinical pediatrics. Bob, you will be sorely missed when you hang up your red pen, always meticulous and always good-humored even with those recalcitrant authors who consistently deliver excuses more readily than their chapters (you know who you are!). There has never been a more exciting time to be in Pediatric Respiratory Medicine. Novel improved prevention strategies such as better immunizations have dramatically reduced infectious diseases and have been key in COVID. Yet global inequity in access to existing effective preventive and treatment options still remains a major hurdle. Fundamental basic science discoveries are giving us transformative novel treatments. Highly effective modulator therapies have transformed the lives in 90% of patients with cystic fibrosis, but sadly only in high income settings, although this still leaves unmet need for specific genotypes. Gene therapy and oral correctors of the Survival Motor Neuron-2 (SMN-2) gene splicing issue have respectively led to many babies with severe spinal muscular atrophy starting to develop normally and improved muscle power in less severe forms of the disease. Biologics targeted at type 2 inflammation mean that the days of chronic oral corticosteroid treatment for severe asthma are passing, and there are many more examples just around the corner. A challenge is the enormous cost of these treatments, and it is a scandal that they are denied to millions of children in low- and middle-income settings because the price has been set unaffordably high. When will we follow the example of antiretroviral treatment, where costs were brought down so that they were freely available at all points of need? There are now ever more powerful techniques to manage the extraordinary big data that are routinely being collected in every setting, from the molecular laboratory to the field of epidemiology. We have also had to grapple with new diseases and their consequences, most notably the COVID pandemic and its aftermath. The authors and editors have extensively refreshed this new volume, the 10th edition. All the chapters have been rewritten. Many authors have retired, and we thank them for earlier contributions. We have nearly 90 new authors and 11 new chapters. As well as standard old favorites, we have a chapter on big data and -omics in respiratory disease, a topic that has exploded since the last edition. COVID has an important place in the chapter on novel respiratory diseases. The evils of vaping and nicotine addiction have a chapter, which is important as the tobacco industry markets aggressively and successfully to children and young people. Increased molecular knowledge has led to hereditary hemorrhagic telangiectasia and pulmonary lymphatic disorders being separated from congenital lung disease and being allocated their own chapters. Obesity and its consequences figure in many chapters as prevalence increases, not least due to worsening child poverty. There is also a huge new library of on-line video resources, especially including bronchoscopic videos thanks to Bob Wood. This greatly augments what was available in the previous edition. Overall, we have attempted to put together a truly international book covering the whole spectrum of our specialty across the globe with a big repository of online resources. It’s an ambitious goal, and we would value feedback for the next edition. Which of your pet topics have we omitted? We will not know unless you tell us, and we aspire to make this the best possible book in ours or (being modest) in any other field. Finally, thanks are due to all who contributed, to Lisa Barnes and Sarah Barth from Elsevier for incredible support, which sometimes even kept us on the straight and narrow, and above all, for the forbearance of our partners. Kendig’s Disorders has yet to be cited in a divorce, and we hope that will continue. Thanks all, and we so hope you enjoy using the volume as much as we did putting it together.